Source: European Medicines Agency (EU) Revision Year: 2022 Publisher: Boehringer Ingelheim International GmbH, Binger Str. 173, 55216 Ingelheim am Rhein, Germany
Pradaxa 150 mg hard capsules.
| Pharmaceutical Form |
|---|
|
Hard capsule. Capsules with light blue, opaque cap and white, opaque body of size 0 (approx. 22 × 8 mm) filled with yellowish pellets. The cap is imprinted with the Boehringer Ingelheim company symbol, the body with “R150”. |
Each hard capsule contains 150 mg of dabigatran etexilate (as mesilate).
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Dabigatran |
Dabigatran etexilate is a small molecule prodrug which does not exhibit any pharmacological activity. After oral administration, dabigatran etexilate is rapidly absorbed and converted to dabigatran by esterase-catalysed hydrolysis in plasma and in the liver. Dabigatran is a potent, competitive, reversible direct thrombin inhibitor and is the main active principle in plasma. |
| List of Excipients |
|---|
|
Capsule content: Tartaric acid Capsule shell: Carrageenan Black printing ink: Shellac |
Perforated aluminium unit dose blisters of 10 × 1 hard capsules. Each carton contains 10, 30 or 60 hard capsules.
Multipack containing 3 packs of 60 × 1 hard capsules (180 hard capsules). Each individual pack of the multipack contains 6 perforated aluminium unit dose blisters of 10 × 1 hard capsules.
Multipack containing 2 packs of 50 × 1 hard capsules (100 hard capsules). Each individual pack of the multipack contains 5 perforated aluminium unit dose blisters of 10 × 1 hard capsules.
Perforated aluminium unit dose white blisters of 10 × 1 hard capsules. Each carton contains 60 hard capsules.
Polypropylene bottle with a screw cap containing 60 hard capsules.
Not all pack sizes may be marketed.
Boehringer Ingelheim International GmbH, Binger Str. 173, 55216 Ingelheim am Rhein, Germany
EU/1/08/442/009
EU/1/08/442/010
EU/1/08/442/011
EU/1/08/442/012
EU/1/08/442/013
EU/1/08/442/016
EU/1/08/442/019
Date of first authorisation: 18 March 2008
Date of latest renewal: 08 January 2018
| Drug | Countries | |
|---|---|---|
| PRADAXA | Austria, Australia, Brazil, Canada, Cyprus, Ecuador, Estonia, Spain, Finland, France, Hong Kong, Croatia, Ireland, Israel, Italy, Lithuania, Netherlands, New Zealand, Poland, Romania, Singapore, Tunisia, Turkey, United Kingdom, United States, South Africa |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
